Today, I’m proud to share that Condor Software has closed a $24 million Series A, led by Insight Partners, with participation from Felicis, 645 Ventures, Pamir Ventures, and SNR Ventures.
A lot has changed since I founded Condor five years ago. Our team has grown, our platform has blossomed into a true Financial Intelligence layer purpose-built for life sciences, and many emerging biotechs and leading biopharma organizations like Acadia Pharmaceuticals, Alumis Therapeutics, BridgeBio Pharma, and Madrigal Pharmaceuticals, now rely on Condor to manage over $19 billion in R&D spend.
What hasn’t changed is our mission: to empower life sciences companies to see, predict, and control the cost of bringing life-changing therapies to patients.
I’ve seen firsthand that good therapies can save lives. Earlier in my career, I worked closely with teams bringing treatments to patients who had run out of options. I built the accounting workflows that the pharmaceutical industry uses to manage clinical trial finances. I saw what it meant, to families, to clinicians, to entire communities, when a therapy worked. And I also saw how financial uncertainty could stall momentum.
I founded Condor because I believe life sciences companies deserve better. They deserve the ability to see, predict, and control the cost of bringing life-changing therapies to patients.
While we’ve made a lot of progress, we still have our work cut out for us. Many life sciences R&D teams still manage clinical trial finances on spreadsheets. Critical decisions about which therapies move forward are made using data that is fragmented, manually reconciled, and often months out of date.
What gets me and everyone else at Condor out of bed in the morning is witnessing accounting, FP&A, and clinical operations teams have that aha-moment when they turn on our platform.
For example, the CFO of a growing biotech recently told us that for the first time, they could see exactly where their clinical trial dollars were going. No spreadsheets stitched together late at night. No uncertainty heading into board meetings. Just a clear, trusted view of trial spend, forecasts, and risk. She said, “For the first time, I feel like we’re making proactive decisions instead of explaining surprises.”
That shift from reactive to proactive is everything. When you have better visibility, you make better decisions, and drive better outcomes.
Stories like that remind us that what we’re building isn’t just software. It’s infrastructure that influences which therapies reach patients.
Our Series A underscores that we have a winning vision and a platform that’s delivering real impact. But more importantly, it gives us the resources to take Condor to the next level by expanding our platform, deepening our enterprise capabilities, and growing our extraordinary team.
Thanks to our customers, employees, and investors for being such an important part of our journey. And stay tuned for more exciting news coming soon!
—Jen
